Unknown Manufacturer
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
MAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system.
For the treatment of moderate to severe hypertension.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
